Tech Times on MSN
A drug that erases an immune protein entirely enters rheumatoid arthritis trials without JAK inhibitor safety warnings
Evommune licensed a drug that erases an immune protein to bypass JAK inhibitor warnings; Caldera added a TL1A bispecific from the same Chinese partner.
<?xml encoding="utf-8" ?> Lexicon Pharmaceuticals LXRX reported third-quarter financial results on Thursday. The transcript ...
For young adults, betting platforms like Kalshi and Polymarket present an opportunity for quick gains. One user tells us how ...
Teams face a potentially wet, unpredictable São Paulo Grand Prix. Changing Weather, tyre deg & Formula 1's 2026 power unit ...
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA ...
Senior Vice President and Chief Financial Officer - Scott Coiante ...
Democrats' November 3 congressional win triggered a tech stock split: SpaceX/Tesla fell while broader tech rallied.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results